Cancer incidence and treatment disparities: a perspective from model island communities of haida gwaii in british columbia comparing first nations (fn) and general population

S37 _________________________________________________________________________________________________________ specificity: 98.1%), the risk of failure is 9.8% (8/82) for patients not having received ADT. For patients who received ADT, the predictive factors of failure are PSA-60 (OR:53.9 p < 0.0001) and T-Stage (OR:0.25 p = 0.0008). Using this model and a PSA-60 cutoff of 0.1 ng/mL (sensitivity: 85%, specificity: 92.9%), the predicted risk of BF in the rising PSA group is 53.7% (36/56). Taking into account the two predictive models, the anticipated cure rate for the entire cohort is 89.7%. Conclusions: Patients treated with LDR-PB monotherapy and whose PSA-60 is ≤ 0.3 ng/mL are highly likely to be cured even if they experienced a slight PSA rise. However, for patients who also received ADT, a stricter cut-off of 0.1 ng/mL may be appropriate.